Table 4.

MGH-SFI item scores by ADT group and gender (safety sample)

MGH-SFI item	Bupropion plus aripiprazole, mean (SE)			SSRI/SNRI plus aripiprazole, mean (SE)
	Baseline	Change from baseline at Week 52 (OC)	Change from baseline at Week 52 (LOCF)	Baseline	Change from baseline at Week 52 (OC)	Change from baseline at Week 52 (LOCF)
Males, n	13	5	13	69	21	69
Interest in sex	2.8 (0.3)	-0.2 (0.9)	0.0 (0.4)	3.8 (0.2)	-0.5 (0.4)	-0.3 (0.2)
Ability to get sexually aroused	3.1 (0.3)	0.0 (0.8)	-0.1 (0.3)	3.9 (0.2)	-0.8 (0.3)	-0.3 (0.2)
Ability to achieve orgasm	3.2 (0.4)	-0.4 (1.1)	-0.2 (0.4)	4.0 (0.2)	-0.7 (0.4)	-0.4 (0.2)
Ability to get erection	3.7 (0.4)	-1.2 (0.4)	-0.6 (0.2)	3.7 (0.2)	-0.3 (0.4)	-0.2 (0.2)
Overall sexual satisfaction	3.9 (0.4)	-1.4 (0.2)	-0.7 (0.3)	4.1 (0.2)	-0.6 (0.3)	-0.4 (0.2)
Females, n	24	14	24	147	48	147
Interest in sex	3.9 (0.3)	-0.5 (0.3)	-0.5 (0.3)	4.6 (0.1)	-0.9 (0.2)	-0.9 (0.1)
Ability to get sexually aroused	4.0 (0.3)	-0.4 (0.5)	-0.5 (0.3)	4.6 (0.1)	-0.9 (0.2)	-0.7 (0.1)
Ability to achieve orgasm	3.9 (0.4)	-0.3 (0.5)	-0.3 (0.3)	4.6 (0.1)	-0.8 (0.2)	-0.7 (0.1)
Overall sexual satisfaction	4.1 (0.3)	-0.8 (0.4)	-0.7 (0.3)	4.7 (0.1)	-1.1 (0.2)	-0.8 (0.1)

ADT, antidepressant treatment; LOCF, last observation carried forward; MGH-SFI, Massachusetts General Hospital Sexual Functioning Inventory; OC, observed case; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

MGH-SFI item scores range from 1 (greater than normal) to 6 (totally absent). A negative change score signifies improvement.